Research programme: proto oncogene protein c-myc inhibitors - Suzhou Kintor Pharmaceuticals
Latest Information Update: 28 Mar 2025
At a glance
- Originator Peking University
- Developer Suzhou Kintor Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in China
- 21 Sep 2022 Preclinical trials in Solid tumours in China (unspecified route) prior to September 2022 (Suzhou Kintor Pharmaceuticals pipeline, September 2022).
- 04 Feb 2021 Research programme: proto oncogene protein c-myc inhibitors - Suzhou Kintor Pharmaceuticals is available for licensing as of 04 Feb 2021. https://en.kintor.com.cn/